Business Context and Reporting Period
Company: Crinetics Pharmaceuticals, Inc. (CRNX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Crinetics is a commercial-stage pharmaceutical company focused on endocrine diseases and tumors. In September 2025, the company received FDA approval for its lead product, PALSONIFY (paltusotine), the first once-daily oral treatment for acromegaly. The company launched PALSONIFY in the U.S. in October 2025, marking a transition from a purely clinical-stage entity to one with commercial operations. The pipeline includes atumelnant (for CAH and ADCS) and CRN09682 (for NETs).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $7,696 | $1,039 | +641% |
| - Product Revenue (PALSONIFY) | $5,420 | $0 | N/A |
| - Collaboration & License Revenue | $2,276 | $1,039 | +119% |
| Operating Expenses | $524,465 | $339,893 | +54% |
| - R&D Expenses | $332,058 | $240,156 | +38% |
| - SG&A Expenses | $191,331 | $99,737 | +92% |
| - Cost of Product Revenue | $1,076 | $0 | N/A |
| Net Loss | $(465,317) | $(298,408) | +56% |
| Cash & Investments (Dec 31, 2025) | $1,027,889 | $1,354,069 | -24% |
| Accumulated Deficit | $(1,417,427) | $(952,110) | N/A |
Note: Cost of product revenue for 2025 was low ($1.1M) because inventory sold was manufactured prior to approval and expensed as R&D, resulting in a zero cost basis for those units.
Material Changes vs. Prior Period
- Revenue Generation: The company generated $5.4 million in net product revenue in 2025, its first year of commercial sales, compared to zero in 2024. This was driven by the October 2025 launch of PALSONIFY.
- Expense Growth: Operating expenses increased by 54% to $524.5 million. SG&A expenses nearly doubled (+92%) due to the build-out of the commercial infrastructure (sales, marketing, market access). R&D expenses rose 38% to $332.1 million, driven by clinical advancement of paltusotine (Phase 3 for Carcinoid Syndrome) and atumelnant (Phase 3 for CAH).
- Liquidity Position: Cash and investment securities decreased by $326 million during 2025 due to operating burn. However, in January 2026 (post-period), the company completed an underwritten public offering raising approximately $380 million, bringing total liquidity to approximately $1.4 billion.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Commercialization: Management expects product revenue to increase as commercialization efforts expand, but does not expect revenue to offset operating expenses in the near term. The company anticipates continued net losses for the foreseeable future.
- Pipeline Milestones:
- PALSONIFY: EMA CHMP adopted a positive opinion in February 2026; a decision is expected in the first half of 2026. Phase 3 study for Carcinoid Syndrome (CS) enrolled its first patient in November 2025.
- Atumelnant: Phase 3 CALM-CAH study randomized its first patient in December 2025. Pediatric Phase 2/3 study (BALANCE-CAH) dosed its first patient in January 2026. Phase 2/3 study for ADCS (EQUILIBRIUM-ADCS) is expected to initiate in H1 2026.
- CRN09682: First patient dosed in Phase 1/2 study in November 2025.
Risks and Contingencies
- Capital Requirements: The company requires substantial additional financing to fund operations and development. While the Jan 2026 offering provides a runway of at least 12 months, future dilution or debt financing may be necessary.
- Commercial Execution: Success depends on market acceptance, payer reimbursement, and the ability to compete with injectable somatostatin analogs. The company has limited experience in commercial operations.
- Regulatory & Clinical: Risks include failure of ongoing clinical trials, delays in regulatory approvals (especially outside the U.S.), and potential safety issues.
- Third-Party Reliance: The company relies entirely on third-party CMOs for manufacturing and CROs for clinical trials, creating supply chain and execution risks.
Investor Verification Checklist
- Commercial Uptake: Verify the rate of patient enrollment and prescriber adoption for PALSONIFY in Q1 2026 to assess if revenue growth is accelerating as projected.
- Reimbursement Status: Confirm the status of formulary inclusion and reimbursement rates with major payers, as this is critical for long-term revenue sustainability.
- Cash Burn Rate: Monitor quarterly operating cash burn to ensure the $1.4 billion liquidity position (post-Jan 2026 offering) remains sufficient to fund the expanded pipeline and commercial operations through 2027.
- EMA Decision: Track the European Commission's final decision on PALSONIFY marketing authorization, expected in H1 2026, which is a key value inflection point.
- Atumelnant Data: Review upcoming data readouts from the CALM-CAH and BALANCE-CAH studies to validate the clinical value proposition for the second major asset.